# DBVT catalysts: DBV Technologies S.A. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/dbvt/catalysts

> DBV Technologies S.A. (DBVT) has no upcoming catalysts in this calendar. The latest recorded is the dbv712 250 mcg topline data readout, Nov 2026 to Feb 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | DBV Technologies S.A. |
| Ticker | DBVT (Nasdaq) |
| SEC CIK | 1613780 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/dbvt |

## Cash runway

Cash $165.7M as of 2026-09-30; quarterly burn $51.5M; about 9.7 months of runway at that rate (XBRL company facts, accession 0001628280-26-067930).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| August 3, 2020 | [Peanut complete response letter (CRL)](https://sec-api.dev/pdufa/peanut) | DBVT |  | completed, complete response letter | "COMPLETE RESPONSE letter dated 08/03/2020 for BL 125713 to DBV Technologies S.A.." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA125713_20200803.pdf%22)) |
| Jun 2022 | [VIASKIN (viaskin) topline data readout](https://sec-api.dev/pdufa/viaskin) | DBVT | peanut-allergic toddlers 1 - 3 years of age | completed, positive | "In June 2022, the Company announced positive topline results from Part B of the Company's EPITOPE phase 3 study assessing the safety and efficacy of the Viaskin Peanut patch for the treatment of peanut-allergic toddlers 1 - 3 years old ("EPITOPE")." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1613780/000162828025046809/dbvt-20250930.htm)) |
| April 30, 2025 | [DBV Technologies S.A. earnings report](https://sec-api.dev/companies/dbvt/catalysts) | DBVT |  | completed | "DBV Technologies Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1613780/000119312525107505/d947872dex991.htm)) |
| May 13, 2025 | [Dbv712 250 mcg primary completion](https://sec-api.dev/pdufa/dbv712) | DBVT | Peanut Allergy | completed | "NCT03859700 (Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-13 (ACTUAL); Lead Sponsor DBV Technologies; Results First Posted 2026-10-28." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03859700)) |
| July 29, 2025 | [DBV Technologies S.A. earnings report](https://sec-api.dev/companies/dbvt/catalysts) | DBVT |  | completed | "DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1613780/000119312525168148/d945712dex991.htm)) |
| Q4 2025 | [DOC-2016 topline data readout](https://sec-api.dev/pdufa/doc-2016) | DBVT |  | scheduled | "Cash and cash equivalents amounted to $32.5 million as of December 31, 2024, compared to $141.4 million as of December 31, 2023, a net cash consumption of $108.9 million, mainly driven by external clinical trial-related expenses, in particular those related to subject enrollment in the Companys ongoing VITESSE Phase 3 clinical trial, with topline results expected by the fourth quarter of 2025 as previously communicated, as well as regulatory and manufacturing activities to support ongoing clinical trials." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1613780/000119312525060850/d932759dex991.htm)) |
| October 28, 2025 | [DBV Technologies S.A. earnings report](https://sec-api.dev/companies/dbvt/catalysts) | DBVT |  | completed | "DBV Technologies Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1613780/000119312525253968/d53703dex991.htm)) |
| November 6, 2025 | [Viaskintm peanut primary completion](https://sec-api.dev/pdufa/viaskintm-peanut) | DBVT | Allergy, Peanut | completed | "NCT05741476 (Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-11-06 (ACTUAL); Lead Sponsor DBV Technologies." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05741476)) |
| Dec 2025 | [DBV Technologies S.A. topline data readout](https://sec-api.dev/companies/dbvt/catalysts) | DBVT |  | completed, positive | "Finally, in December 2025, the Company reported positive topline results from the Phase 3 VITESSE trial in peanut-allergic children aged 4 to 7 years that enable a BLA filing expected in the first half of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1613780/000162828026028929/dbvt-20260331.htm)) |
| December 16, 2025 | [VIASKIN (viaskin) topline data readout](https://sec-api.dev/pdufa/viaskin) | DBVT |  | completed, positive | "On December 16, 2025, the Company announced positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1613780/000162828026021504/dbvt-20251231.htm)) |
| January 16, 2026 | [DBV Technologies S.A. topline data readout](https://sec-api.dev/companies/dbvt/catalysts) | DBVT |  | completed, positive | "On January 16, 2026, the Company announced additional gross proceeds of $195 million (€166.7 million at the exchange rate of 1 EUR = $1.17) resulting from the full exercise of the ABSA Warrants and BS Warrants, following the announcement of the positive VITESSE Topline Results on December 16, 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1613780/000162828026021504/dbvt-20251231.htm)) |
| March 26, 2026 | [DBV Technologies S.A. earnings report](https://sec-api.dev/companies/dbvt/catalysts) | DBVT |  | completed | "DBV Technologies Reports Full Year 2025 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1613780/000119312526126671/d113165dex991.htm)) |
| April 30, 2026 | [DBV Technologies S.A. earnings report](https://sec-api.dev/companies/dbvt/catalysts) | DBVT |  | completed | "DBV Technologies Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1613780/000119312526197921/d132063dex991.htm)) |
| Q3 2026 | [VIASKIN (viaskin) NDA/BLA submission](https://sec-api.dev/pdufa/viaskin) | DBVT |  | scheduled | "Continued productive engagement with the FDA in support of the BLA for the VIASKIN® Peanut Patch in children aged 4 through 7 years, with submission of the BLA anticipated in the third quarter of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1613780/000119312526306222/d156695dex991.htm)) |
| July 16, 2026 | [DBV Technologies S.A. earnings report](https://sec-api.dev/companies/dbvt/catalysts) | DBVT |  | completed | "DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1613780/000119312526306222/d156695dex991.htm)) |
| October 28, 2026 | [DBV Technologies S.A. earnings report](https://sec-api.dev/companies/dbvt/catalysts) | DBVT |  | completed | "DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1613780/000119312526436411/d137106dex991.htm)) |
| October 28, 2026 | [Dbv712 250 mcg topline data readout](https://sec-api.dev/pdufa/dbv712) | DBVT | Peanut Allergy | completed | "NCT03859700 (Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-13 (ACTUAL); Lead Sponsor DBV Technologies; Results First Posted 2026-10-28." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03859700?tab=results)) |
| November 2026 | [Dbv712 250 mcg primary completion](https://sec-api.dev/pdufa/dbv712) | DBVT | Allergy; Peanut Allergy | scheduled | "NCT07003919 (Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor DBV Technologies." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07003919)) |
| Nov 2026 to Feb 2027 | [Dbv712 250 mcg topline data readout](https://sec-api.dev/pdufa/dbv712) | DBVT | Allergy; Peanut Allergy | scheduled | "NCT07003919 (Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor DBV Technologies." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07003919)) |

## Drugs

- [Dbv712 250 mcg](https://sec-api.dev/pdufa/dbv712): Peanut Allergy, Allergy
- [DOC-2016](https://sec-api.dev/pdufa/doc-2016): 
- [Peanut](https://sec-api.dev/pdufa/peanut): 
- [VIASKIN (viaskin)](https://sec-api.dev/pdufa/viaskin): peanut-allergic toddlers 1 - 3 years old, peanut-allergic toddlers 1 - 3 years of age
- [Viaskintm peanut](https://sec-api.dev/pdufa/viaskintm-peanut): Allergy, Peanut

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/dbvt/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "DBVT catalysts: DBV Technologies S.A. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/dbvt/catalysts

```bibtex
@misc{secapidev_companies_dbvt_catalysts_20261116,
  title        = {DBVT catalysts: DBV Technologies S.A. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/dbvt/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_dbvt_catalysts_20261116","title":"DBVT catalysts: DBV Technologies S.A. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/dbvt/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
